Atea Financial Statements From 2010 to 2024

AVIR Stock  USD 3.70  0.03  0.80%   
Atea PharmaceuticalsI financial statements provide useful quarterly and yearly information to potential Atea PharmaceuticalsInc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atea PharmaceuticalsI financial statements helps investors assess Atea PharmaceuticalsI's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Atea PharmaceuticalsI's valuation are summarized below:
Gross Profit
-81.9 M
Market Capitalization
313.9 M
Enterprise Value Revenue
58.974
Revenue
192.2 M
Earnings Share
(1.63)
There are over one hundred nineteen available fundamental signals for Atea PharmaceuticalsInc, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Atea PharmaceuticalsI's prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 04/25/2024, Market Cap is likely to drop to about 241.6 M. In addition to that, Enterprise Value is likely to drop to about 107.3 M

Atea PharmaceuticalsI Total Revenue

192.18 Million

Check Atea PharmaceuticalsI financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea main balance sheet or income statement drivers, such as Net Interest Income of 30.7 M, Interest Income of 30.7 M or Depreciation And Amortization of 436.8 K, as well as many exotic indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.0 or PTB Ratio of 0.48. Atea financial statements analysis is a perfect complement when working with Atea PharmaceuticalsI Valuation or Volatility modules.
  
This module can also supplement Atea PharmaceuticalsI's financial leverage analysis and stock options assessment as well as various Atea PharmaceuticalsI Technical models . Check out the analysis of Atea PharmaceuticalsI Correlation against competitors.

Atea PharmaceuticalsI Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets541.8 M595 M251.7 M
Slightly volatile
Other Current Liabilities20.6 M27.4 M9.6 M
Slightly volatile
Total Current Liabilities57 M32.4 M33.3 M
Slightly volatile
Other Liabilities6.3 MM1.7 M
Slightly volatile
Property Plant And Equipment Net3.3 M3.1 M740 K
Slightly volatile
Accounts Payable2.3 M4.3 M1.2 M
Slightly volatile
Cash136.6 M143.8 M191.6 M
Slightly volatile
Non Current Assets Total4.7 M4.5 M1.2 M
Slightly volatile
Non Currrent Assets Other1.5 M1.4 M373.5 K
Slightly volatile
Other Assets0.951.0223.3 K
Slightly volatile
Cash And Short Term Investments530.8 M578.1 M246.8 M
Slightly volatile
Common Stock Total Equity50.9 K95.5 K33 K
Slightly volatile
Common Stock Shares Outstanding85.7 M83.4 M62.1 M
Slightly volatile
Liabilities And Stockholders Equity541.8 M595 M251.7 M
Slightly volatile
Non Current Liabilities TotalM7.4 M48 M
Slightly volatile
Other Current Assets7.8 M12.3 M3.5 M
Slightly volatile
Other Stockholder Equity500 M750.7 M217.3 M
Slightly volatile
Total Liabilities78.3 M39.8 M82.2 M
Very volatile
Property Plant And Equipment GrossM3.8 M863.1 K
Slightly volatile
Total Current Assets539.7 M590.5 M250.7 M
Slightly volatile
Capital Stock64.3 K95.5 K33.9 K
Slightly volatile
Non Current Liabilities Other7.2 M6.8 M1.8 M
Slightly volatile
Net Working Capital461.3 M558.1 M216.1 M
Slightly volatile
Common Stock64.3 K95.5 K33.9 K
Slightly volatile
Property Plant Equipment4.9 M4.7 M957.4 K
Slightly volatile
Net Receivables4.7 M5.2 M5.7 M
Slightly volatile
Capital Surpluse696.8 M752.1 M633.2 M
Slightly volatile
Short and Long Term Debt Total2.1 M2.4 M665.9 K
Slightly volatile
Capital Lease Obligations2.1 M2.4 M665.9 K
Slightly volatile

Atea PharmaceuticalsI Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income30.7 M29.2 MM
Slightly volatile
Interest Income30.7 M29.2 MM
Slightly volatile
Depreciation And Amortization436.8 K416 K88.7 K
Slightly volatile
Selling General Administrative47.4 K49.9 K9.7 M
Slightly volatile
Other Operating Expenses108.5 M164.2 M51.7 M
Slightly volatile
Research Development76.7 M114.2 M36.6 M
Slightly volatile
Total Operating Expenses108.4 M163.7 M51.7 M
Slightly volatile
Reconciled Depreciation436.8 K416 K88.7 K
Slightly volatile
Total Other Income Expense Net30.7 M29.2 MM
Slightly volatile
Cost Of Revenue436.8 K416 K88.7 K
Slightly volatile
Non Operating Income Net Other162.8 K244.9 K116.5 K
Slightly volatile
Selling And Marketing Expenses39.6 M44.5 M48.5 M
Slightly volatile

Atea PharmaceuticalsI Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.4 M49.4 M11.6 M
Slightly volatile
Begin Period Cash Flow343.7 M188.5 M155.9 M
Slightly volatile
Depreciation436.8 K416 K88.7 K
Slightly volatile
Issuance Of Capital Stock196.7 K207 K59.2 M
Pretty Stable
End Period Cash Flow136.6 M143.8 M161.1 M
Slightly volatile
Change To Netincome49.8 M47.4 M12.7 M
Slightly volatile
Sale Purchase Of Stock1.3 M1.3 M390.3 M
Slightly volatile
Change To Inventory4.1 M4.6 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.32.4252.5307
Slightly volatile
Days Sales Outstanding34.9139.2842.7697
Slightly volatile
Invested Capital0.00270.00430.0035
Slightly volatile
Stock Based Compensation To Revenue0.140.130.1455
Slightly volatile
Payables Turnover0.120.09780.0635
Slightly volatile
Sales General And Administrative To Revenue0.140.150.363
Slightly volatile
Research And Ddevelopement To Revenue0.690.550.7195
Slightly volatile
Cash Per Share5.436.93263.4669
Slightly volatile
Days Payables Outstanding3.5 K3.7 K12.4 K
Very volatile
Current Ratio13.2118.237417.9973
Pretty Stable
Receivables Turnover6.697.538.1963
Slightly volatile
Graham Number16.4115.62795.7753
Slightly volatile
Debt To Equity0.00270.00430.0035
Slightly volatile
Revenue Per Share1.943.821.3823
Slightly volatile
Days Of Payables Outstanding3.5 K3.7 K12.4 K
Very volatile
Ebt Per Ebit1.030.8220.9553
Very volatile
Long Term Debt To Capitalization0.00370.00290.0037
Slightly volatile
Total Debt To Capitalization0.00270.00430.0035
Slightly volatile
Debt Equity Ratio0.00270.00430.0035
Slightly volatile
Quick Ratio16.317.85619.6919
Very volatile
Net Income Per E B T0.771.00750.947
Slightly volatile
Cash Ratio4.224.442316.3377
Slightly volatile
Days Of Sales Outstanding34.9139.2842.7697
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9827
Slightly volatile
Fixed Asset Turnover14.4 K13.7 K4.7 K
Slightly volatile
Price Sales Ratio2.32.4252.5307
Slightly volatile
Asset Turnover0.210.410.1432
Slightly volatile
Gross Profit Margin0.80.90.9797
Slightly volatile
Operating Cycle34.9139.2842.7697
Slightly volatile

Atea PharmaceuticalsI Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap241.6 M254.3 M1.4 B
Slightly volatile

Atea Fundamental Market Drivers

Cash And Short Term Investments578.1 M

Atea Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atea PharmaceuticalsI Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea PharmaceuticalsI income statement, its balance sheet, and the statement of cash flows. Atea PharmaceuticalsI investors use historical funamental indicators, such as Atea PharmaceuticalsI's revenue or net income, to determine how well the company is positioned to perform in the future. Although Atea PharmaceuticalsI investors may use each financial statement separately, they are all related. The changes in Atea PharmaceuticalsI's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea PharmaceuticalsI's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea PharmaceuticalsI Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea PharmaceuticalsI. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(0.90)(0.85)
Total Revenue192.2 M0.0
Cost Of Revenue416 K436.8 K
Stock Based Compensation To Revenue 0.13  0.14 
Sales General And Administrative To Revenue 0.15  0.14 
Research And Ddevelopement To Revenue 0.55  0.69 
Capex To Revenue(0.00001)(0.000011)
Revenue Per Share 3.82  1.94 
Ebit Per Revenue 0.35  0.37 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atea PharmaceuticalsI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atea PharmaceuticalsI's short interest history, or implied volatility extrapolated from Atea PharmaceuticalsI options trading.

Pair Trading with Atea PharmaceuticalsI

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.

Moving against Atea Stock

  0.57ACB Aurora Cannabis TrendingPairCorr
  0.51CGC Canopy Growth Corp TrendingPairCorr
  0.5ELYM Eliem TherapeuticsPairCorr
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Atea PharmaceuticalsInc is a strong investment it is important to analyze Atea PharmaceuticalsI's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Atea PharmaceuticalsI's future performance. For an informed investment choice regarding Atea Stock, refer to the following important reports:
Check out the analysis of Atea PharmaceuticalsI Correlation against competitors.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Atea Stock analysis

When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.641
Earnings Share
(1.63)
Revenue Per Share
2.31
Quarterly Revenue Growth
2.952
Return On Assets
(0.12)
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.